Creative Animodel has partnered with more than 10 research institutes and hospitals to get access to versatile patient-derived tumor xenograft (PDX) models with well-defined molecular characteristics for your individual study. Patient samples adopted to establish PDX models in Creative Animodel are from either treat-naïve or resistant patients, which enabling genetic and phenotypic heterogeneity retaining after the engraftment into highly immune-deficient NSG mice.
Creative Animodel has built a relatively complete PDX model bank for immediate execution of in vivo tests including the following cancer species but not limited to:
|Acute Myeloid Leukemia||-||Query|
|Acute Lymphoblastic Leukemia||-||Query|
|Bladder Cancer||Urothelial Carcinoma Invasive||Query|
|Invasive Ductal Carcinoma||Query|
|Metaplastic Spindle Cell Carcinoma||Query|
|Mixed Ductal Carcinoma||Query|
|Ductal Carcinoma In Situ||Query|
|Head & Neck Cancer||-||Query|
|Lung Cancer||NSCLC: Adenocarcinoma||Query|
|NSCLC: metastatic adenocarcinoma||Query|
|Ovarian Cancer||Ovarian serous adenocarcinoma||Query|
|Papillary serous adenocarcinoma||Query|
|Ovary serous adenocarcinoma||Query|
|Pancreatic Cancer||Pancreatic Ductal Adenocarcinoma||Query|
|Ampulla of Vater Adenocarcinoma||Query|
PDX models can offer the closest available alternative to clinical testing for researchers who need to evaluate cancer drug efficacy, for the reason that this kind of models retain primary tumor properties and metastasis behavior. Creative Animodel created models using dissociated tumor cells from biopsies that can better reflect the heterogeneity and sophistication of tumors, which will benefit the preclinical drug candidates screening procedure. Our PDX models can satisfy customers in the researches on molecular characteristics as well as the biological functions of the primary tumors cells, which include migration, metastasis, drug resistance, and tumor relapse. The advanced PDX models, in alliance with our traditionally existing cultured cell line-derived xenograft models, offer customers a more broad range of testing options for potential cancer therapies.
Ex-vivo Tumor Patient Study Platform
In addition, patient-derived tumor ex vivo study platform has been established by Creative Animodel to extend tissues or primary cells-related researches. This platform directly delivers the primary cancer cells or tissues to ex vivo compound activity profiling which enabling an extensive survey of drug response in diverse disease background. Based on our widespread cooperation with research and clinical institutes, Creative Animodel also renders customized service for PDX models other than the referred tumors. Please feel free to contact us for more information or to get access to your individual projects involving with preclinical drug evaluation or biomarker identification.